公开(公告)号：US3830700A

公开(公告)日：1974-08-20

申请号：US29464972

申请日：1972-10-03

Applicant: GLAXO LAB LTD

Inventor： O CALLAGHAN C ,  KIRBY S ,  HEATH I ,  CLARK J ,  KENNEDY J ,  SHINGLER A ,  WEIR N ,  LONG A ,  MORRIS A

IPC: C07D501/22 ,  C07D501/24 ,  C12Q1/34 ,  C12K1/00 ,  G01N31/22

CPC classification number: C12Q1/34 ,  C12Q2334/00 ,  G01N2333/986 ,  G01N2415/00 ,  Y10S435/805

Abstract: WHERE R IS AMINO OR BLOCKED AMINO, X IS -S-, -SO(A OR B) OR -S2-, AND AR IS A CARBOCYCLE OR A HETEROCYCLE SUBSTITUTED BY AT LEAST ONE ELECTRON WITHDRAWING SUBSTITUENT IN CONJUGATION WITH THE EXOCYCLIC -CH=CHDOUBLE BOND,AND SALTS AND ESTERS ARE USEFUL CHROMOGENIC AGENTS FOR THE DETECTION OF B-LACTAMASE ACTIVITY. TEST REAGENTS CONTAINING SUCH COMPOUNDS ARE ALSO DISCLOSED.

1,2-(-C(-COOH)=C(-CH=CH-AR)-CH2-X-),3-R-AZETIDIN-4-ONE

CEPHALOSPORIN COMPOUNDS HAVING THE FORMULA

公开(公告)号：US3790567A

公开(公告)日：1974-02-05

申请号：US3790567D

申请日：1971-12-28

Applicant: GLAXO LAB LTD

Inventor： KENNEDY J ,  LONG A ,  ELPHINSTONE W

IPC: A61K31/545 ,  B21C37/26 ,  C07D409/04 ,  C07D409/12 ,  C07D501/04 ,  C07D501/24 ,  C07D501/26 ,  C07D501/32 ,  C07D99/24

CPC classification number: C07D409/04 ,  A61K31/545 ,  C07D409/12 ,  C07D501/26 ,  C07D501/32

Abstract: 7B-ACYLAMINODOCEPH-3-EM-4-CARBOXYLIC ACIDS HAVING AN ETHERIFIED HYDROXYMETHYL GROUP AT THE 3-POSITION AND PHYSIOLOGICALLY ACCEPTABLE DERIVATIVES THEREOF. THE COMPOUNDS HAVE UTILITY AS ANTIBIOTICS AND SHOW ABSORPTION AFTER ORAL ADMINISTRATION.

公开(公告)号：US3846416A

公开(公告)日：1974-11-05

申请号：US21318871

申请日：1971-12-28

Applicant: GLAXO LAB LTD

Inventor： ELPHINSTONE W ,  KENNEDY J ,  LONG A

IPC: C07D501/32 ,  C07D99/24

CPC classification number: C07D501/32

Abstract: 7 Beta -Acylamidoceph-3-em-4-carboxylic acids having an etherified hydroxymethyl group at the 3-position and physiologically acceptable derivatives thereof. The compounds have utility as antibiotics and show absorption after oral administration.

Abstract translation: 7位在3-位具有醚化羟甲基的β-酰胺基头孢-3-烯-4-羧酸及其生理上可接受的衍生物。 该化合物具有作为抗生素的作用，并且在口服给药后显示吸收。

公开(公告)号：US3830808A

公开(公告)日：1974-08-20

申请号：US21319371

申请日：1971-12-28

Applicant: GLAXO LAB LTD

Inventor： CLARK J ,  KENNEDY J ,  LONG A

IPC: A61K31/545 ,  C07D501/36 ,  G01G21/04 ,  C07D99/24

CPC classification number: C07D501/36 ,  A61K31/545

Abstract: 7B-ACYLAMIDOCEPH-3-EM-4-CARBOXYLIC ACIDS HAVING A THIOETHERIFIED METHYL GROUP AT THE 3-POSITION AND PHYSIOLOGICALLY ACCEPTABLE THEREOF. THE COMPOUNDS HAVE UTILITY AS ANTIBIOTICS AND SHOW ABSORPTION AFTER ORAL ADMINISTRATION.

公开(公告)号：DK143657C

公开(公告)日：1982-03-01

申请号：DK494072

申请日：1972-10-06

Applicant: GLAXO LAB LTD

Inventor： O'CALLAGHAN C H ,  CLARK J C ,  KENNEDY J ,  KIRBY S M ,  LONG A G ,  MORRIS A ,  SHINGLER A H ,  WEIR N G

IPC: C07D501/22 ,  C07D501/24 ,  C12Q1/34

公开(公告)号：YU255673A

公开(公告)日：1982-02-28

申请号：YU255673

申请日：1973-09-27

Applicant: GLAXO LAB LTD

Inventor： EARDLEY S ,  KENNEDY J ,  LONG A G

IPC: A61K31/545 ,  C07D501/00

公开(公告)号：SE380270B

公开(公告)日：1975-11-03

申请号：SE849369

申请日：1969-06-13

Applicant: GLAXO LAB LTD

Inventor： CLARK J C ,  KENNEDY J ,  LONG A G ,  WILSON E M

IPC: A61K31/545 ,  C07D501/36 ,  G01G21/04

公开(公告)号：CA924302A

公开(公告)日：1973-04-10

申请号：CA27932

申请日：1968-08-20

Applicant: GLAXO LAB LTD

Inventor： KENNEDY J ,  LONG A ,  WILSON E

IPC: C07D501/04 ,  C07C29/54 ,  C07D501/18

公开(公告)号：ZA7100429B

公开(公告)日：1972-09-27

申请号：ZA7100429

申请日：1971-01-22

Applicant: GLAXO LAB LTD

Inventor： CLARK J ,  WEIR N ,  KENNEDY J ,  LONG A

IPC: C07D501/04 ,  C07D501/20 ,  C07D501/22 ,  C07F9/6539 ,  C07F9/6561 ,  C07D

CPC classification number: C07F9/6539 ,  C07F9/65613

公开(公告)号：GB1241655A

公开(公告)日：1971-08-04

申请号：GB3849267

申请日：1967-08-21

Applicant: GLAXO LAB LTD

Inventor： KENNEDY J ,  LONG A ,  WILSON E

IPC: C07D501/04 ,  C07C29/54 ,  C07D501/18

Abstract: 1,241,655. N-Deacylating cephalosporin compounds. GLAXO LABORATORIES Ltd. 6 Aug., 1968 [21 Aug., 1967], No. 38492/67. Heading C2A. 7# - Acylamino - 4 - carboxy - cephalosporin compounds (other than those having at position- 7 a #-aminoadipoylamino group which are optionally blocked at the amino and/or carboxy groups) are N-deacylated by reacting with an imide-halide-forming reagent, converting the resulting imide halide into an imino ether and hydrolysing or alcoholysing the latter to give a 7#-amino-cephalosporin compound. The 4- carboxyl group of the starting material is preferably blocked, e.g. by esterification with an easily removable esterifying group such as a diphenylmethyl, t-butyl, #,#,#-trichloroethyl or silyl group. Any other functional groups which may be present are blocked if necessary. Typical 7#-acyl groups which may be removed are thienylacetyl, phenylacetyl, phenoxyacetyl, benzoyl and acetyl. The starting materials may have at the 3-position a methyl, hydroxymethyl, etherified hydroxymethyl, or acyloxymethyl group or a group derived from a nucleophile. Suitable imide-halide-forming agents are acid halides of phosphorus acids, e.g. phosphorus oxychloride or pentachloride. The reaction is preferably effected in an inert organic solvent in the presence of a base such as triethylamine, pyridine, dimethylaniline or calcium carbonate. Conversion to the imino ether is preferably by reacting with an alcohol, e.g. methanol, in the presence of a tertiary amine such as listed above. The imino-ether may be decomposed with water or an alkanol in the presence of an acidic or basic catalyst, e.g. hydrochloric, trifluoroacetic, toluenesulphonic, phosphoric or formic acids, or ammonia or salts of a weak acid with alkali- or alkaline earth-metals. The N-deacylated products are useful as intermediates for re-acylation by a different 7#-acylating group to give antibiotically active cephalosporin compounds.